Drug Search Results
More Filters [+]

Chymotrypsin

Alternative Names: chymotrypsin, alphachymotrypsin
Latest Update: 2024-08-20
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Protein Hydrolyzer

Novel Mechanism: No

Modality: N/A

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Canada | Chile | Egypt | India | Ireland | Italy | Korea | Morocco | New Zealand | Pakistan | Peru | Poland | Portugal | Russia | Spain | Switzerland | Taiwan | Ukraine | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Healthgen Biotechnology
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Chymotrypsin

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Pleurisy

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HY1005-2023-2-P1

P1

Not yet recruiting

Pleurisy

2025-07-01

Recent News Events

Date

Type

Title